Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022
Agios Pharmaceuticals (NASDAQ: AGIO) will host a conference call and live webcast on November 3, 2022, at 8:00 a.m. ET to discuss its third quarter 2022 financial results and business updates.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agios Pharmaceuticals (NASDAQ: AGIO) will host a conference call and live webcast on November 3, 2022, at 8:00 a.m. ET to discuss its third quarter 2022 financial results and business updates. The webcast will be accessible on the company’s website in the Investors section and will be archived for later replay. Agios is recognized for its pioneering work in therapies for rare and genetically defined diseases, including a first-in-class pyruvate kinase activator for PK deficiency. The company continues to advance its clinical pipeline targeting various blood disorders.
Positive
- Agios markets a first-in-class pyruvate kinase activator for adults with PK deficiency.
- The company is advancing a robust clinical pipeline targeting diseases like sickle cell disease and thalassemia.
Negative
- None.
Details
News Market Reaction – AGIO
The recorded move for AGIO in the trading session of this news was -0.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced the company will host a conference call and live webcast on Thursday, November 3, 2022, at 8:00 a.m. ET to report its third quarter 2022 financial results and other business highlights.
A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.
About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare and genetically defined diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with active and planned programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has multiple investigational therapies in preclinical development and an industry-leading research team with unmatched expertise in cellular metabolism and genetics. For more information, please visit the company’s website at www.agios.com.
Contacts
Investors:
Holly Manning, 617-844-6630
Senior Director, Investor Relations
Holly.Manning@agios.com
Media:
Jessica Rennekamp, 857-209-3286
Senior Director, Corporate Communications
Jessica.Rennekamp@agios.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.